Properties (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
natalizumab
|
| gptkbp:administrativeDivision |
every 4 weeks
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Tysabri
|
| gptkbp:chemicalFormula |
C6460H10080N1716O2016S44
|
| gptkbp:clinicalTrials |
Phase III
long-term therapy |
| gptkbp:contraindication |
anemia
depression dizziness muscle pain weight loss abdominal pain cough fever sore throat swelling diarrhea joint pain muscle weakness insomnia sepsis chills nervousness weight gain active infections skin rash anaphylaxis thrombocytopenia urinary tract infections visual disturbances history_of_PML |
| gptkbp:developedBy |
gptkb:Biogen
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:formulation |
sterile liquid
|
| gptkbp:hasPopulation |
adults
pediatric patients |
| https://www.w3.org/2000/01/rdf-schema#label |
Tysabri
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count JCV_antibody_status |
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2004
|
| gptkbp:mandates |
relapsing forms of multiple sclerosis
severe Crohn's disease |
| gptkbp:marketedAs |
gptkb:Tysabri
|
| gptkbp:patentExpiration |
2023
|
| gptkbp:riskManagement |
infusion reactions
hypersensitivity reactions progressive multifocal leukoencephalopathy |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
MRI scans
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
headache nausea infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
integrin antagonist
|
| gptkbp:usedFor |
Crohn's disease
multiple sclerosis |
| gptkbp:weight |
145 kDa
|